[ad_1]
Neu-Isenburg.
The advantages of mRNA vaccines are emphasized over and over again: rapid production in large quantities and high safety, since mRNA is an endogenous molecule that also breaks down very quickly in the body. For SARS-CoV-2 candidate vaccines, mRNA vaccines are therefore particularly promising.
“I guess we will have a good security profile,” said Professor Ugur Sahin of BioNTech. In May, the company will test the first phase I clinical trial with four candidate mRNA vaccines against the new coronavirus. The first data could be available in July.
From previous preclinical studies and from the few clinical studies with mRNA vaccines, there is no evidence of serious undesirable effects: as with other vaccines, the immunostimulatory activity of mRNA vaccines can cause undesirable effects, such as redness at the injection site , fever and general malaise. Sahin reported at a Science Media Center event.
“We are already seeing polymorphisms”
Until the vaccine became available, the virus probably would not have changed so much that the vaccine would no longer work. “We already see polymorphisms in SARS-CoV-2, but not as often in protein S,” said Sahin. With this protein, SARS-CoV-2 is known to bind to your target cells.
Currently, there is no evolutionary pressure for the virus, as there is still no vaccine available. “We probably won’t see any dramatic changes in the next 6 to 18 months.”
The big question, which is a decisive factor especially in a pandemic situation, is the dose: the final dose, which is sufficient for effective protection from vaccination, “may be in the range of single, two or three digit micrograms. digits, “says Sahin.
“We can answer this question more reliably in July and August. Basically billions of cans would be needed worldwide, “this requires more than one manufacturer and more than one product.”
